Medication info
Memantine Tablets 5 mg (Memantine Hydrochloride)

Memantine Tablets 5 mg (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›5mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
White round film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202502817 · Approved 2025.10.30 · Insurance code 698505140

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, the dose may be increased to 20mg once daily at least 7 days after administration, following the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease. It helps improve the patient's memory decline and cognitive function, and helps maintain daily living abilities. Additionally, it contributes to the alleviation of behavioral symptoms in patients, thereby enhancing quality of life.

How to take

Adult dose

This medicine is administered orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, the dose may be increased to 20mg once daily at least 7 days after administration, following the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be used by patients who are allergic to any of its ingredients. It should also not be administered to patients with severely impaired liver function or significantly reduced kidney function. This medication contains lactose and should not be taken by patients with lactose intolerance or certain genetic lactose metabolism disorders. Patients with epilepsy or a history of seizures should use this medication cautiously, and those at a high risk of seizures should also exercise caution. Co-administration with other NMDA antagonists may increase the risk of side effects, hence combination should be avoided. Caution is warranted in patients with factors that change urine acidity (pH) or with cardiovascular disease and uncontrolled hypertension. Side effects may include dizziness, headache, constipation, drowsiness, and hypertension, among others, and various neurological and gastrointestinal adverse reactions have been reported. There are drug interactions, especially with certain antipsychotic medications, skeletal muscle relaxants, anticoagulants, and caution is advised when using them together. Women who are pregnant or may become pregnant should carefully consider the risks and benefits before use, as the use of this medication may be hazardous. Nursing mothers are advised to discontinue breastfeeding as this medication could be excreted in breast milk. Safety and efficacy for children and adolescents under 18 years have not been established. In case of overdose, central nervous system symptoms and gastrointestinal symptoms may appear, and immediate medical attention should be sought. This medication may affect the speed of response and concentration in patients, thus caution is advised when driving or operating machinery. When storing, keep out of reach of children and do not transfer to another container.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucination
  • psychotic reaction
Show 24 more
  • balance disorder
  • gait abnormality
  • seizure
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function test levels
  • hepatitis
  • fatigue
  • nonspecific fatigue
  • weakness
  • diarrhea
  • agitation
  • aggression
  • delirium
  • unconsciousness
  • restlessness
  • psychosis
  • visual hallucinations
  • convulsion
  • coma
  • double vision

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air exposure, at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

White round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.